Plasma Protein Therapeutics Market By Product type (Immunoglobulin, Albumin, Plasma derived factor VIII, Others), By Application (Hemophilia, Idiopathic thrombocytopenic purpura, Primary immunodeficiency disorder, Others), By End user (Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031

Plasma Protein Therapeutics Market

A class of biopharmaceuticals known as plasma protein therapeutics is derived from human blood plasma and used to treat a wide range of diseases. Blood contains naturally occurring substances called plasma proteins, which are crucial for maintaining health and preventing disease. They are used to treat various disorders such as immune deficiencies, hemophilia, infectious diseases, autoimmune diseases and bleeding disorders. Several types of plasma protein therapeutics such as immunoglobulins, plasma derived factors, albumins and other among these are used for the treatment of these diseases. 

Key factors driving the growth of the plasma protein therapeutics market include rise in demand for the advanced therapeutics. Plasma protein therapies are preferred as patients and medical professionals search for better, more specialized treatments for a variety of diseases. Key drivers of the rise demand for advanced medicines are rise in the aging population, the need for more efficient treatments for these conditions, the rise in autoimmune illnesses and other chronic diseases. 

The plasma protein therapeutics market is experiencing significant growth due to the rise in adoption of strategies by key market players. These strategies are aimed at expanding their market presence and product portfolios, which in turn drives the growth of the market. Agreement and acquisition are major strategies adopted by the market players. For an instance, in September 2022, Grifols a global leader in plasma medicines announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions. Thus, adoption of such strategies drives the market growth. 

In addition, an increase in product approval and product development for plasma protein products is expected to drive the growth of the plasma protein therapeutics market. For an instance in November 2022, Biotest AG announced today that the German competent authority, the Paul-Ehrlich-Institute, has approved the new intravenous immunoglobulin Yimmugo (IgG Next Generation) in Germany. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIG). Thus, significant product approval drives the market growth.   

However, the market for plasma protein treatments is anticipated to experience growth restrictions due to stringent rules for handling plasma protein products. Because of the importance of these products and their effects on human health, the plasma protein industry is subject to strict regulation. Conversely, technological advancement is a major opportunity for the growth of the plasma protein therapeutics market. Advances in technology and research have enabled the development of new and innovative plasma protein therapeutics that offer improved outcomes for patients. 

The plasma protein therapeutics market is segmented into product type, application, end user and region. By product type, the market is categorized into immunoglobulin, albumin, plasma factor derived VIII, and others. By application, the market is segregated into hemophilia, idiopathic thrombocytopenic purpura , primary immunodeficiency, and others. By end user, the market is categorized into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).   

The key players profiled in the study include ADMA Biologics Inc, Bayer AG, Bio products laboratory, Baxter International, CSL Limited, Grifsols, Kedrion SpA, Octapharma USA Inc, Taibang Biological Group Co. Ltd, and Takeda Pharmaceutical Company Limited. The players in the market have been actively engaged in the adoption various strategies such as collaboration, agreement, product approval, product development and acquisition to remain competitive and gain advantage over the competitors in the market. For instance, in July 2021, Octapharma announced that The U.S. Food and Drug Administration (FDA) has granted approval for OctagamR. 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.

Key Market Insights (Updated) 

By product type the immunoglobulin segment was highest contributor to the market in 2021 with highest CAGR during the forecast period.  

By application, the hemophilia segment dominated the market in 2021. However, primary immunodeficiency is anticipated to grow at highest CAGR during the forecast period.   

Based on end user, the hospital segment was the largest revenue contributor to the market in 2021 and is estimated to reach $32,538.33 million by 2031, with a CAGR of 5.1%. 

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The global plasma protein therapeutics market was valued at $26.5 billion in 2021, and is projected to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

Plasma protein therapeutics are a subcategory of biopharmaceuticals made from human blood plasma and are used to treat a range of diseases. Natural components called plasma proteins are present in blood and are essential for preserving good health and preventing disease. Various compounds, such as immunoglobulin, clotting factors, albumin, and other specialized plasma proteins, are included in the category of plasma protein therapies. These medicines are used to treat a range of illnesses, such as Kawasaki disease, immunological deficiencies, blood problems, liver ailments, autoimmune diseases, and neurological disorders such as chronic polyneuropathy. 

The market for plasma protein therapeutics is driven by factors such as an increase in the prevalence of chronic diseases with unmet needs, rise in an aging population, and advancements in protein therapies technology and rise in R&D in the plasma protein field. The demand for these products is expected to continue to grow due to an increase in the incidence of chronic immunological diseases, particularly in developing countries. In addition, new product development and new product approval are significant drivers of growth for the plasma protein therapeutics market. For an instance, in February 2020 CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted Privigenne (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc).  Moreover, market growth is also driven by market participants forming strategic alliances and working together with universities, research facilities, and other organizations. Furthermore, companies are acquiring smaller players to expand their product portfolio, increase their market presence, and gain access to new markets. Thus, the rise in adoption of strategies by key market players, such as mergers and acquisitions, product innovation, and expanding distribution networks, is driving the growth of the plasma protein therapeutics market.  

 There is an increase in the demand for plasma protein therapeutics as patients and medical professionals prefer more effective and specific treatments for a variety of diseases, including immunological disorders and autoimmune disorders. They offer a variety of advantages over traditional treatment, including improved efficacy, fewer side effects, and the ability to target specific disease-related molecules.

In addition, plasma protein therapeutics have been gaining significant attention in recent years due to their potential to treat a wide range of medical conditions, including immune disorders, and bleeding disorders. Rise in demand for advanced therapeutics, as patients and healthcare professionals look for more effective and focused therapies for various diseases also drives the market growth.   

However, stringent guidelines for storage, testing, and collection from donors, of plasma is expected to restrain the growth of the plasma protein therapeutics market. On the other hand, development of targeted plasma protein therapies that can be used to treat specific disorders has been made possible by modifications in analytical and diagnostic technologies. Research and technological advancements have made it possible to create novel plasma protein therapies that improve patient outcomes. Thus, technological advancements in the field of plasma protein therapeutics offer a significant opportunity for market growth.  

The plasma protein therapeutics market is segmented into product type, application, end user and region. By product type, the market is categorized into immunoglobulin, albumin, plasma factor derived VIII, and others. By application, the market is segregated into hemophilia, idiopathic thrombocytopenic purpura , primary immunodeficiency, and others. By end user, the market is categorized into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major key players that operate in the global plasma protein therapeutics market are ADMA Biologics Inc, Bayer AG, Bio products laboratory, Baxter International, CSL Limited, Grifsols, Kedrion SpA, Octapharma USA Inc, Taibang Biological Group Co. Ltd, and Takeda Pharmaceutical Company Limited.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the plasma protein therapeutics market analysis from 2021 to 2031 to identify the prevailing plasma protein therapeutics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the plasma protein therapeutics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global plasma protein therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Taibang Biological Group Co., Lt

Scope of Plasma Protein Therapeutics Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in demand for advanced therapeutics

3.4.1.2. Rise in adoption of strategies by key market players

3.4.1.3. Increase in product approval and product development

3.4.2. Restraints

3.4.2.1. Strict regulation for handling plasma protein products

3.4.3. Opportunities

3.4.3.1. Technological advancements

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Immunoglobulin

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Albumin

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Plasma derived factor VIII

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Hemophilia

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Idiopathic thrombocytopenic purpura

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Primary immunodeficiency disorder

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Others

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Others

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Product type

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End user

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Product type

7.2.5.1.3. Market size and forecast, by Application

7.2.5.1.4. Market size and forecast, by End user

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Product type

7.2.5.2.3. Market size and forecast, by Application

7.2.5.2.4. Market size and forecast, by End user

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Product type

7.2.5.3.3. Market size and forecast, by Application

7.2.5.3.4. Market size and forecast, by End user

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Product type

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End user

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Product type

7.3.5.1.3. Market size and forecast, by Application

7.3.5.1.4. Market size and forecast, by End user

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Product type

7.3.5.2.3. Market size and forecast, by Application

7.3.5.2.4. Market size and forecast, by End user

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Product type

7.3.5.3.3. Market size and forecast, by Application

7.3.5.3.4. Market size and forecast, by End user

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Product type

7.3.5.4.3. Market size and forecast, by Application

7.3.5.4.4. Market size and forecast, by End user

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Product type

7.3.5.5.3. Market size and forecast, by Application

7.3.5.5.4. Market size and forecast, by End user

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Product type

7.3.5.6.3. Market size and forecast, by Application

7.3.5.6.4. Market size and forecast, by End user

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Product type

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End user

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Product type

7.4.5.1.3. Market size and forecast, by Application

7.4.5.1.4. Market size and forecast, by End user

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Product type

7.4.5.2.3. Market size and forecast, by Application

7.4.5.2.4. Market size and forecast, by End user

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Product type

7.4.5.3.3. Market size and forecast, by Application

7.4.5.3.4. Market size and forecast, by End user

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Product type

7.4.5.4.3. Market size and forecast, by Application

7.4.5.4.4. Market size and forecast, by End user

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Product type

7.4.5.5.3. Market size and forecast, by Application

7.4.5.5.4. Market size and forecast, by End user

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Product type

7.4.5.6.3. Market size and forecast, by Application

7.4.5.6.4. Market size and forecast, by End user

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Product type

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End user

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Product type

7.5.5.1.3. Market size and forecast, by Application

7.5.5.1.4. Market size and forecast, by End user

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Product type

7.5.5.2.3. Market size and forecast, by Application

7.5.5.2.4. Market size and forecast, by End user

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Product type

7.5.5.3.3. Market size and forecast, by Application

7.5.5.3.4. Market size and forecast, by End user

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Product type

7.5.5.4.3. Market size and forecast, by Application

7.5.5.4.4. Market size and forecast, by End user

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Octapharma AG

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Grifols, S.A.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Baxter International Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. ADMA Biologics Inc

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Bio Products Laboratory Ltd

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Key strategic moves and developments

9.6. Takeda Pharmaceutical Company Limited

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. CSL Limited

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Kedrion, SpA

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Taibang Biological Group Co., Ltd

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.10. Bayer AG

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 02. PLASMA PROTEIN THERAPEUTICS MARKET FOR IMMUNOGLOBULIN, BY REGION, 2021-2031 ($MILLION)

TABLE 03. PLASMA PROTEIN THERAPEUTICS MARKET FOR ALBUMIN, BY REGION, 2021-2031 ($MILLION)

TABLE 04. PLASMA PROTEIN THERAPEUTICS MARKET FOR PLASMA DERIVED FACTOR VIII, BY REGION, 2021-2031 ($MILLION)

TABLE 05. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 06. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 07. PLASMA PROTEIN THERAPEUTICS MARKET FOR HEMOPHILIA, BY REGION, 2021-2031 ($MILLION)

TABLE 08. PLASMA PROTEIN THERAPEUTICS MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2021-2031 ($MILLION)

TABLE 09. PLASMA PROTEIN THERAPEUTICS MARKET FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2021-2031 ($MILLION)

TABLE 10. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 12. PLASMA PROTEIN THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 14. PLASMA PROTEIN THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 15. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 16. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 17. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 18. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 20. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 21. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 22. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 23. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 24. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 25. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 26. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 27. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 28. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 29. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 30. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 31. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 32. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 33. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 34. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 35. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 36. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 37. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 38. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 39. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 40. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 41. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 42. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 43. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 44. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 45. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 46. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 47. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 48. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 49. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 50. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 52. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 53. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 54. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 55. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 56. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 57. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 58. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 59. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 60. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 61. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 62. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 63. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 64. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 65. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 66. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 67. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 68. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 72. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 73. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 74. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 75. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 76. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 77. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 78. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 79. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 80. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 81. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 82. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 83. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 84. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 85. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)

TABLE 86. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 87. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 88. OCTAPHARMA AG: KEY EXECUTIVES

TABLE 89. OCTAPHARMA AG: COMPANY SNAPSHOT

TABLE 90. OCTAPHARMA AG: PRODUCT SEGMENTS

TABLE 91. OCTAPHARMA AG: PRODUCT PORTFOLIO

TABLE 92. OCTAPHARMA AG: KEY STRATERGIES

TABLE 93. GRIFOLS, S.A.: KEY EXECUTIVES

TABLE 94. GRIFOLS, S.A.: COMPANY SNAPSHOT

TABLE 95. GRIFOLS, S.A.: PRODUCT SEGMENTS

TABLE 96. GRIFOLS, S.A.: PRODUCT PORTFOLIO

TABLE 97. GRIFOLS, S.A.: KEY STRATERGIES

TABLE 98. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES

TABLE 99. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT

TABLE 100. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS

TABLE 101. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO

TABLE 102. ADMA BIOLOGICS INC: KEY EXECUTIVES

TABLE 103. ADMA BIOLOGICS INC: COMPANY SNAPSHOT

TABLE 104. ADMA BIOLOGICS INC: PRODUCT SEGMENTS

TABLE 105. ADMA BIOLOGICS INC: PRODUCT PORTFOLIO

TABLE 106. ADMA BIOLOGICS INC: KEY STRATERGIES

TABLE 107. BIO PRODUCTS LABORATORY LTD: KEY EXECUTIVES

TABLE 108. BIO PRODUCTS LABORATORY LTD: COMPANY SNAPSHOT

TABLE 109. BIO PRODUCTS LABORATORY LTD: PRODUCT SEGMENTS

TABLE 110. BIO PRODUCTS LABORATORY LTD: PRODUCT PORTFOLIO

TABLE 111. BIO PRODUCTS LABORATORY LTD: KEY STRATERGIES

TABLE 112. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES

TABLE 113. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 114. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS

TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

TABLE 117. CSL LIMITED: KEY EXECUTIVES

TABLE 118. CSL LIMITED: COMPANY SNAPSHOT

TABLE 119. CSL LIMITED: PRODUCT SEGMENTS

TABLE 120. CSL LIMITED: PRODUCT PORTFOLIO

TABLE 121. CSL LIMITED: KEY STRATERGIES

TABLE 122. KEDRION, SPA: KEY EXECUTIVES

TABLE 123. KEDRION, SPA: COMPANY SNAPSHOT

TABLE 124. KEDRION, SPA: PRODUCT SEGMENTS

TABLE 125. KEDRION, SPA: PRODUCT PORTFOLIO

TABLE 126. KEDRION, SPA: KEY STRATERGIES

TABLE 127. TAIBANG BIOLOGICAL GROUP CO., LTD: KEY EXECUTIVES

TABLE 128. TAIBANG BIOLOGICAL GROUP CO., LTD: COMPANY SNAPSHOT

TABLE 129. TAIBANG BIOLOGICAL GROUP CO., LTD: PRODUCT SEGMENTS

TABLE 130. TAIBANG BIOLOGICAL GROUP CO., LTD: PRODUCT PORTFOLIO

TABLE 131. BAYER AG: KEY EXECUTIVES

TABLE 132. BAYER AG: COMPANY SNAPSHOT

TABLE 133. BAYER AG: PRODUCT SEGMENTS

TABLE 134. BAYER AG: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN PLASMA PROTEIN THERAPEUTICS MARKET (2022-2031)

FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. HIGH THREAT OF NEW ENTRANTS

FIGURE 08. HIGH INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPLASMA PROTEIN THERAPEUTICS MARKET

FIGURE 10. PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR IMMUNOGLOBULIN, BY COUNTRY 2021 AND 2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR ALBUMIN, BY COUNTRY 2021 AND 2031(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR PLASMA DERIVED FACTOR VIII, BY COUNTRY 2021 AND 2031(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 15. PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR HEMOPHILIA, BY COUNTRY 2021 AND 2031(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY COUNTRY 2021 AND 2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY COUNTRY 2021 AND 2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 20. PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY 2021 AND 2031(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 23. PLASMA PROTEIN THERAPEUTICS MARKET BY REGION, 2021

FIGURE 24. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 25. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 26. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 27. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 28. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 29. UK PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 30. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 31. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 32. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 33. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 34. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 35. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 36. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 37. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 38. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 39. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 40. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 41. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 42. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47. COMPETITIVE DASHBOARD

FIGURE 48. COMPETITIVE HEATMAP: PLASMA PROTEIN THERAPEUTICS MARKET

FIGURE 49. TOP PLAYER POSITIONING, 2021

FIGURE 50. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 51. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 52. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 53. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 54. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 55. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 56. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. ADMA BIOLOGICS INC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 58. ADMA BIOLOGICS INC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 59. ADMA BIOLOGICS INC: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 60. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 61. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 62. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 63. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 65. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 66. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. BAYER AG: REVENUE SHARE BY REGION, 2022 (%